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ABSTRACT 
Objective: To develop and validate simple zero (D0), first (D1) and second (D2
Methods: Sunitinib malate was solubilised in distilled water and the resultant solution exhibits adsorption maximum (λmax) at 431, 457 and 489 
nm in D
) order derivative UV Spectrophotometric methods for the 
determination of Sunitinib malate in pharmaceutical dosage form. 
0, D1 and D2
Results: Linearity was obtained over the concentration range of 2-12 µg/ml in all the derivative modes. Limit of detection (LOD) was found to be 
0.291, 0.107, 0.327μg/ml and Limit of quantification (LOQ) was found to be 0.883, 0.324, 0.993μg/ml for D
 order derivative modes respectively. The developed method was validated as per ICH guidelines [1]. 
0, D1 and D2
Conclusion: The statistical results prove that the developed method can be effectively applied for the routine analysis of Sunitinib malate in 
industries and other analytical laboratories. 
 order derivative modes 
respectively. The proposed method demonstrated an excellent intra-day precision and inter-day precision. Mean recovery was found within the 
range of 98.19-98.62% respectively, signifies the accuracy of the developed method.  
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Sunitinib malate is described chemically as Butanedioic acid, hydroxy-
(2S)-compound with N-[2-(diethylamino) ethyl]-5-[(Z)-(5-fluoro-1, 2-
dihydro-2-oxo-3H-indol-3-ylidine) methyl]-2, 4-dimethyl-1H-pyrrole-
3-carboxamide (fig. 1), is an orally administered small molecule that 
inhibits multiple receptor tyrosine kinases (RTKs). Sunitinib malate 
was approved by the US Food and Drug Administration (FDA) on 
January 26, 2006, for the treatment of metastatic renal cell 
carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) in 
patients who have failed to respond to imatinib or were unable to 
tolerate it [2-3], with molecular formula C22H27FN4O2 • C4H6O5 
 
and 
molecular weight 532.561g/mol. Sunitinib malate is an orange 
powder which is freely soluble in water. 
 
Fig. 1: Chemical structure of Sunitinib malate 
 
On surveying the literature, it was found that only a very few 
methods have been reported for the estimation of Sunitinib malate 
alone or in combination by employing RP-HPLC and UPLC [4-7]. 
Some of the RP-HPLC and UPLC method were not found to be done 
economical in terms of mobile phase employed and availability of 
columns. Hence there is a need for the development of newer 
method for the estimation of Sunitinib malate in pharmaceutical 
dosage form to overcome the above hurdles. At the same time, no UV 
Spectrophotometric method was reported for the estimation of 
Sunitinib malate. So it is felt worthwhile to develop a modest, rapid, 
accurate, precise and more economical UV Spectrophotometric 
method for the estimation of Sunitinib malate in pharmaceutical 
dosage form.  
MATERIALS AND METHODS 
Chemicals and reagents 
The raw material of Sunitinib malate (99.78%w/w) was obtained a 
gift sample, which was used as reference material throughout the 
experiment without any prior treatment. Sunitinib malate tablets 
(SUTENT Capsule-25 mg, Pfizer Inc.) were purchased from a local 
market. All other reagents used were purchased from Merck 
laboratories and S. D. fine chemicals Ltd. Double distilled water was 
utilized throughout the process of analysis. 
Instruments used 
• Perkin-Elmer UV-Visible Spectrophotometer lambda 25. 
• Digital balance. 
• Sonicator. 
• Class “A” grade glassware’s was used. 
Solubility studies 
The solubility studies of Sunitinib malate was carried out employing 
different solvent, and the results are as follows:  
• Very freely soluble in water.  
• Soluble in alcohol. 
• Slightly Soluble in 0.1N HCl.  
• Slightly Soluble in 0.1N NaOH.  
Selection of solvent 
Sunitinib exists as a salt form of maleic acid and it is found that the 
drug is very freely soluble in water. Hence, water was chosen as the 
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solvent to solubilise Sunitinib malate and to carry out further 
analysis. 
Preparation of standard stock solution of sunitinib malate 
The standard stock solution of Sunitinib malate was prepared by 
accurately weighing 25 mg of the drug and it was kept in a 25 ml 
standard flask. Half the volume of water was added. The solution was 
sonicated for 15 min and then the volume was made up to the mark 
with distilled water. The resultant solution was filtered and suitably 
diluting with distilled water to get the working standard solutions. 
Preparation of sample stock solution 
Twenty capsules (STUTENT Capsule-25 mg, Pfizer Inc.) were 
accurately weighed and the sample stock solution was prepared by 
accurately weighing an amount of Sunitinib malate equivalent to 25 
mg and transferred into a 25 ml standard flask. Half the volume of 
water was added. The solution was sonicated for 20 min and then 
the volume was made up to the mark with distilled water. The 
solution was filtered through Whatman filter paper. The aliquot 
portion of the filtrate was suitably diluting for further analysis. 
Determination of λmax  
The standard stock solution of Sunitinib malate was diluted suitably 
to get a concentration of 10µg/ml. The solution was scanned within 
the range of 200 nm-500 nm in D0, D1 and D2
Method validation 
 order derivative 
modes respectively.  
Linearity 
From the above prepared standard stock solution, 10 ml of the 
solution was diluted to 100 ml using water to get a concentration of 
100µg/ml. From the above solution 2 ml, 4 ml, 6 ml, 8 ml, 10 ml and 
12 ml of solutions were pipetted out into 6 different 100 ml 
volumetric flasks and the volume was made up to 100 ml using 
distilled water to get the final concentrations of 2µg/ml, 4µg/ml, 
6µg/ml, 8µg/ml, 10µg/ml and 12µg/ml respectively. These aliquots 
were scanned in D0, D1 and D2
LOD and LOQ 
 order derivative modes respectively.  
LOD and LOQ were calculated from the data obtained from the 
linearity studies. The slope of the linearity plot and standard 
deviation (SD) of the responses was determined. LOD and LOQ were 
calculated on the basis of SD and slope of the regression equation.  
LOD = (3.3 x SD)/slope LOQ = (10 x SD)/slope 
Precision  
From the above prepared standard stock solution, 10 ml of the 
solution was diluted to 100 ml utilizing water to get a concentration 
of 100µg/ml. From the above solution 4 ml, 6 ml and 8 ml of 
solutions were pipetted out into 3 different 100 ml volumetric flasks 
and the volume was made with distilled water to get the final 
concentrations of 4µg/ml, 6µg/ml and 8µg/ml respectively. The 
intra-day and inter-day analysis was carried out to determine the 
precision of the developed method. These solutions were scanned in 
the three modes six times a day (inter-day precision). The solutions 
were scanned in the three modes for six days at the same time (intra-
day precision). The calculated percentage relative standard deviation 
(% RSD) of the results was used to evaluate the method precision. 
Recovery 
The recovery study was carried out by the standard addition 
method. 10 ml of the standard stock solution of standard and sample 
was pipetted out separately to two 100 ml volumetric flasks and the 
volume was diluted to 100 ml with distilled water to get a 
concentration of 100µg/ml. From the above standard solution 4 ml 
was pipetted out into 4 different volumetric flasks and sample 
solutions of 0 ml, 2 ml, 4 ml and 6 ml were added to the above 4 
volumetric flasks already containing standard solutions and the 
volume was made up to 100 ml with distilled water. The above 
solutions were scanned in the three modes. The percentage recovery 
was estimated. 
Assay 
The sample stock solution of Sunitinib malate was diluted suitably to 
get a concentration of 10µg/ml. The above solution was scanned in 
the three modes and the UV spectra’s were recorded and the 
percentage purity of Sunitinib malate in the pharmaceutical 
formulation was calculated. 
RESULTS AND DISCUSSION 
Selection of detection wavelength 
The λmax was observed at 431, 457 and 489 nm in D0, D1 and D2
 
 
order derivative modes respectively and the UV spectra’s was shown 
in the fig. 2, 3 & 4 respectively. 
 








Fig. 4: UV spectra showing maximum absorbance at D2
 
 mode 
Linearity Linearity of Sunitinib malate by the proposed method was 
made for different concentrations ranging from 2-12 µg/ml was 
recorded in all the three modes respectively. Linearity was found to 
obey Beer’s law in the concentration range employed, and the 
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results were tabulated in table 1. The UV spectra slowing linearity 
and the calibration curves at D0, D1 and D2 modes were presented in 
fig. 5&6, 7&8, 9&10 respectively. 
 
Fig. 5: UV spectra showing linearity at D0 mode 
 
 
Fig. 6: Calibration graph of D0 mode 
 
Fig. 7: UV spectra showing linearity at D1 mode 
 
Fig. 8: Calibration graph of D1 mode 
 
 
Fig. 9: UV spectra showing linearity at D2 mode 
 
 
Fig. 10: Calibration graph of D2
 
 mode 




D D0 D1 2 
Linearity range (µg/ml) 2-12 µg/ml 
Regression equation y=0.048x-0.025 y=0.178x-0.063 y=0.003x-0.001 
Correlation coefficient (r2 0.999 ) 0.999 0.999 
Slope 0.048 0.178 0.003 
Y-Intercept 0.025 0.063 0.001 
SD 0.0075 0.0058 0.0005 
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Table 2: LOD and LOQ values at D0, D1 and D2 
Parameters 
modes 
D0 D Mode 1 D Mode 2 Mode 
LOD (µg/ml) 0.291 0.107 0.327 
LOQ (µg/ml) 0.883 0.324 0.993 
 
LOD and LOQ 
The low SD value of responses, LOD and LOQ indicates that the 
developed method is precise and sensitive. The calculated results 
are listed in table 2. 
Precision 
The intra-day and inter-day precision studies (intermediate 
precision) were performed. The %RSD was considered to be within 
0.470-1.870% (intra-day) and 0.870-1.830% (inter-day) which was 
well within the acceptance criteria, i.e., less than 2% and the results 
were tabulated in table 3&4. 
Recovery 
The percentage recovery of the drug was in the range of 97.20-
99.36% w/w, which was well within the acceptance limit of 97-
103% w/w as per ICH guidelines and the results were tabulated in 
table 5. 
Assay 
The mean percentage assay was found to be 97.32-102.28% w/w.  
The UV spectra’s were shown in fig. 11, 12 & 13 and the results were 
listed in table 6. 
 
Table 3: Intra-day precision at D0, D1 and D2 
Mode 
modes 
D D0 D1 2 
Concentration 
(µg/ml) 
4 6 8 4 6 8 4 6 8 
Absorbance 0.1659 0.2573 0.3714 0.5831 0.9342 1.3384 0.0100 0.0155 0.0219 
0.1639 0.2548 0.3753 0.5820 0.9332 1.3392 0.0096 0.0156 0.0226 
0.1626 0.2541 0.3672 0.5813 0.9350 1.3389 0.0098 0.0158 0.0215 
0.1632 0.2557 0.3702 0.5792 0.9338 1.3402 0.0099 0.0159 0.0223 
0.1645 0.2568 0.3692 0.5840 0.9351 1.3368 0.0099 0.0152 0.0225 



















%R.S.D 0.720 0.470 0.740 0.540 0.620 0.095 1.700 1.650 1.870 
mean±SD* = average of six determinations 
 
Table 4: Inter-day precision at D0, D1 and D2 modes 
Mode D0 D1 D2 
Concentration 
(µg/ml) 
4 6 8 4 6 8 4 6 8 
Absorbance 0.1659 0.2573 0.3714 0.5831 0.9342 1.3384 0.0100 0.0155 0.0219 
0.1644 0.2610 0.372 0.5734 0.9430 1.3440 0.0099 0.0158 0.0223 
0.1660 0.2582 0.3623 0.5728 0.9229 1.3560 0.0099 0.0162 0.0215 
0.1643 0.2600 0.3719 0.5801 0.9448 1.3652 0.0102 0.0160 0.0223 
0.1672 0.2632 0.3682 0.5790 0.9280 1.3620 0.0101 0.0163 0.0225 





















%R. S. D 0.870 1.016 1.053 1.260 1.010 1.030 1.470 1.830 1.630 
mean±SD* = average of six determinations 
 
Table 5: Recovery studies at D0, D1 and D2 
Mode 
modes 
Amount present (µg/ml) Amount added (µg/ml) Absorbance Amount recovered (µg/ml) % Recovery Mean (±SD)* 
D 4 0 0 0.1715 3.9745 99.36  
98.620±0.9654 4 2 0.2685 5.8881 97.20 
4 4 0.3705 7.9592 98.98 
4 6 0.4934 9.9576 98.94 
D 4 1 0 0.6591 3.9663 99.16  
98.375±0.6456 4 2 1.0293 5.952 97.60 
4 4 1.3896 7.9298 98.24 
4 6 1.8408 9.9100 98.50 
D 4 2 0 0.0098 3.9596 98.99  
98.1925±0.5901 4 2 0.0162 5.9632 98.16 
4 4 0.0203 7.9219 98.05 
4 6 0.0286 9.7945 97.57 
 mean±SD* = average of four determinations 
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Table 6: Assay at D0, D1 and D2 
Mode 
modes 
Theoretical yield (mg) Practical yield (mg) Percentage yield (%w/w) 
D 24.33 0 25 97.32 
D 24.925 1 25 99.70 
D 25.57 2 25 102.28 
 
 
Fig. 11: UV spectra showing assay at D0 mode 
 
 
Fig. 12: UV spectra showing assay at D1 mode 
 
 
Fig. 13: UV spectra showing assay at D2
Sunitinib malate is an oral, small-molecule, multi-targeted receptor 
tyrosine kinase (RTK) inhibitor that was approved by the FDA for 
the treatment of renal cell carcinoma (RCC) and imatinib-resistant 




It was the first cancer drug that was approved. The development of a 
simple, rapid, sensitive and precise Spectrophotometric method for 
the routine quantitative determination of samples will definitely 
reduce unnecessary tedious sample preparations and the cost of 
materials and labour. Sunitinib malate is a UV-absorbing molecule 
with specific chromophores in the structure that absorbs at a 
particular wavelength and this fact was successfully employed for 
their quantitative determinations using the UV Spectroscopic 
method and validating the same. The λmax was observed at 431, 457 
and 489 nm in D0, D1 and D2
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